HHLR ADVISORS LTD. 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | HHLR ADVISORS LTD. | 238,857 8.200% | 146,466 (+158.53%) | Filing |
| 2023-02-14 4:10 pm Sale | 2022-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | HHLR ADVISORS LTD. | 92,391 5.800% | -2,212 (-2.34%) | Filing |
| 2022-02-14 4:08 pm Purchase | 2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | HHLR ADVISORS LTD. | 94,603 5.600% | 8,000 (+9.24%) | Filing |
| 2021-02-16 4:27 pm Purchase | 2020-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | HHLR ADVISORS LTD. | 86,603 5.700% | 86,603 (New Position) | Filing |